Sarah M Jabour1, Sara Beachy2, Shayna Coburn3,4, Sophie Lanzkron5, Michelle N Eakin6. 1. Division of General Internal Medicine, Johns Hopkins University, Baltimore, MD, USA. 2. Department of Education and Health Services, Lehigh University, Bethlehem, PA, USA. 3. Children's National Health System, Washington, D.C., USA. 4. The George Washington University, Washington, D.C., USA. 5. Division of Hematology, Johns Hopkins University, Baltimore, MD, USA. 6. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, 5501 Hopkins Bayview Blvd., Room 4B.74, Baltimore, MD, 21224, USA. meakin1@jhu.edu.
Abstract
OBJECTIVE: This qualitative study analyzed the perspective of patients living with sickle cell disease (SCD) on their process of deciding whether to take hydroxyurea (HU), and the role of physician communication in patients' decision-making process. METHODS: From October 2015 to July 2016, we conducted semi-structured interviews among patients with SCD (N = 20) that were audio-recorded and transcribed. Participants were ≥ 18 years old, a patient of an urban adult sickle cell center, able to provide informed consent, and English-speaking. We iteratively developed codes and used thematic analysis to organize the key themes. RESULTS: Most participants were female (65%), middle aged (M = 44, SD = 12.2), and 55% were prescribed HU for an average of 10.4 (SD = 4.7) years. Participants described 3 key factors that influenced their decision regarding HU treatment: (1) lifestyle, (2) health status, and (3) HU characteristics. Four themes emerged about provider communication and HU treatment decisions: (1) provider's advisement, (2) shared decision-making, (3) "wrestled," and (4) not feeling heard. CONCLUSION: Providers who engaged in shared decision-making empowered participants to decide whether to start HU treatment. Participants who felt their providers were not listening to their concerns expressed disengaging from HU treatment. During discussions about HU with patients living with SCD, providers must understand the multi-faceted aspects that impact patients' decision and empower patients to engage in such discussions. Further research is needed to understand the role of shared decision-making among patients with SCD to improve management of SCD.
OBJECTIVE: This qualitative study analyzed the perspective of patients living with sickle cell disease (SCD) on their process of deciding whether to take hydroxyurea (HU), and the role of physician communication in patients' decision-making process. METHODS: From October 2015 to July 2016, we conducted semi-structured interviews among patients with SCD (N = 20) that were audio-recorded and transcribed. Participants were ≥ 18 years old, a patient of an urban adult sickle cell center, able to provide informed consent, and English-speaking. We iteratively developed codes and used thematic analysis to organize the key themes. RESULTS: Most participants were female (65%), middle aged (M = 44, SD = 12.2), and 55% were prescribed HU for an average of 10.4 (SD = 4.7) years. Participants described 3 key factors that influenced their decision regarding HU treatment: (1) lifestyle, (2) health status, and (3) HU characteristics. Four themes emerged about provider communication and HU treatment decisions: (1) provider's advisement, (2) shared decision-making, (3) "wrestled," and (4) not feeling heard. CONCLUSION: Providers who engaged in shared decision-making empowered participants to decide whether to start HU treatment. Participants who felt their providers were not listening to their concerns expressed disengaging from HU treatment. During discussions about HU with patients living with SCD, providers must understand the multi-faceted aspects that impact patients' decision and empower patients to engage in such discussions. Further research is needed to understand the role of shared decision-making among patients with SCD to improve management of SCD.
Authors: Otis W Brawley; Llewellyn J Cornelius; Linda R Edwards; Vanessa Northington Gamble; Bettye L Green; Charles Inturrisi; Andra H James; Danielle Laraque; Magda Mendez; Carolyn J Montoya; Brad H Pollock; Lawrence Robinson; Aaron P Scholnik; Melissa Schori Journal: Ann Intern Med Date: 2008-05-05 Impact factor: 25.391
Authors: Sherif M Badawy; Alexis A Thompson; Jin-Shei Lai; Frank J Penedo; Karen Rychlik; Robert I Liem Journal: Pediatr Blood Cancer Date: 2016-11-28 Impact factor: 3.167
Authors: Carlton Haywood; Marie Diener-West; John Strouse; C Patrick Carroll; Shawn Bediako; Sophie Lanzkron; Jennifer Haythornthwaite; Gladys Onojobi; Mary Catherine Beach Journal: J Pain Symptom Manage Date: 2014-04-15 Impact factor: 3.612
Authors: Carlton Haywood; Sophie Lanzkron; Shawn Bediako; John J Strouse; Jennifer Haythornthwaite; C Patrick Carroll; Marie Diener-West; Gladys Onojobi; Mary Catherine Beach Journal: J Gen Intern Med Date: 2014-09-10 Impact factor: 5.128
Authors: Lori E Crosby; Ashley Walton; Lisa M Shook; Russell E Ware; Marsha Treadwell; Kay L Saving; Maria Britto; James Peugh; Emily McTate; Suzette Oyeku; Cara Nwankwo; William B Brinkman Journal: J Pediatr Hematol Oncol Date: 2019-01 Impact factor: 1.289